Related Experiment Video

Updated: May 14, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinson's disease

V Isella1, C Mapelli, N Morielli

  • 1Neurology Section, S. Gerardo Hospital, University of Milan Bicocca, Via Pergolesi 33, 20900, Monza (MB), Italy, valeria.isella@unimib.it.

Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|February 21, 2013
PubMed

Insights

The MiniMental Parkinson (MMP) offers improved screening for cognitive issues in Parkinson's disease (PD) patients compared to the MiniMental State Examination (MMSE). While showing promise, its specificity needs further refinement for optimal diagnostic use.

Area of Science:

  • Neurology
  • Psychometrics

Background:

  • Cognitive impairment is common in Parkinson's disease (PD).
  • Existing screening tools like the MiniMental State Examination (MMSE) may not fully capture the specific cognitive deficits in PD.
  • The MiniMental Parkinson (MMP) scale was developed to address these limitations.

Purpose of the Study:

  • To evaluate the psychometric properties and validity of the MMP scale.
  • To compare the screening ability of the MMP against the MMSE in Parkinson's disease patients.

Main Methods:

  • A multicenter study involving 69 cognitively intact and 52 cognitively impaired Parkinson's disease patients.
  • Patients were classified using the Dementia Rating Scale.
  • Psychometric properties, convergent validity, and screening ability were assessed.

Main Results:

  • The MMP demonstrated better metrics, convergent validity, and higher screening ability than the MMSE.
  • However, the MMP's performance showed limitations in data distribution, coefficient of variation, and specificity.
  • Receiver Operating Characteristic (ROC) curve analysis did not reveal a clear superiority for either scale at optimal trade-offs.

Conclusions:

  • The MMP scale is slightly preferable to the MMSE for screening cognitive impairment in Parkinson's disease, particularly when prioritizing sensitivity over specificity.
  • The test is quick and simple to administer.
  • Further validation is needed to address limitations in specificity and overall validity.

More Related Videos

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Traditional Trail Making Test Modified into Brand-new Assessment Tools: Digital and Walking Trail Making Test08:07

Traditional Trail Making Test Modified into Brand-new Assessment Tools: Digital and Walking Trail Making Test

Published on: November 23, 2019

Related Concept Videos

Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...